To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients

NCT07201467 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

End-Stage Renal Disease Requiring Haemodialysis

Interventions

DRUG: KN060

Sponsor

Suzhou Alphamab Co., Ltd.